Form 4: Enliven Therapeutics CEO Sells Shares Under 10b5-1 Plan

Samuel Kintz, President and CEO of Enliven Therapeutics, sold 6,000 shares of common stock in September 2025 through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO of Enliven Therapeutics, Inc. (ELVN), reported two sales of common stock.
• On September 17, 2025, Kintz sold 5,000 shares at a weighted average price of $19.0946 per share.
• On September 19, 2025, Kintz sold an additional 1,000 shares at a weighted average price of $20.25 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following these sales, Kintz beneficially owns 921,892 shares of common stock, held directly and indirectly through The Kintz & Egan Trust.

Sentiment

Score: 5

Explanation: While insider selling can be viewed negatively, the execution under a pre-established 10b5-1 plan mitigates concerns that the sales are based on new, undisclosed negative information. It's a planned liquidity event, resulting in a neutral sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to recent negative company news.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this transactional filing.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

Industry Context

This insider transaction report does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• Shares are held indirectly by The Kintz & Egan Trust Dated March 30, 2019, for which the reporting person serves as trustee.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially leading to minor short-term price fluctuations, though the 10b5-1 plan context often lessens this impact.

Key Dates

Recommendation

This Form 4 reports routine insider selling under a pre-established 10b5-1 plan, which typically does not signal a fundamental change in the company's prospects. While insider selling can sometimes be a negative signal, the planned nature of these transactions suggests personal financial planning rather than a reaction to adverse company developments. Therefore, it does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Common Stock